Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer

Cancer Research

Volumn 70, Issue 2, 2010, Pages 842-851

  Narayanan, Ramesh ^a   Yepuru, Muralimohan ^a   Szafran, Adam T ^b   Szwarc, Maria ^b   Bohl, Casey E ^a   Young, Natalie L ^a   Miller, Duane D ^a   Mancini, Michael A ^b   Dalton, James T ^a  

^a GTx Inc   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; SELECTIVE NUCLEAR ANDROGEN RECEPTOR EXPORTER; UNCLASSIFIED DRUG;

ARTICLE; BONE CELL; CELLULAR DISTRIBUTION; ENZYME INHIBITION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TRANSACTIVATION; TUMOR XENOGRAFT; UBIQUITINATION;

ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL NUCLEUS; CERCOPITHECUS AETHIOPS; COS CELLS; HELA CELLS; HUMANS; MALE; MICE; MICE, NUDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROPANOLAMINES; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSCRIPTIONAL ACTIVATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 76549097089     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3206     Document Type: Article

References (36)

1. Zeigler-Johnson CM, Rennert H, Mittal RD, et al. Evaluation of prostate cancer characteristics in four populations worldwide. Can J Urol 2008;15:4056-64.
2. Zhu ML, Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 2008;15:841-9.
3. De Marzo AM, DeWeese TL, Platz EA, et al. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 2004;91:459-77.
4. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008;8:440-8.
5. Wang X, Yin L, Rao P, et al. Targeted treatment of prostate cancer. J Cell Biochem 2007;102:571-9.
6. Claessens F, Denayer S, Van Tilborgh N, et al. Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl Recept Signal 2008;6:e008.
7. Roy AK, Tyagi RK, Song CS, et al. Androgen receptor: structural domains and functional dynamics after ligand-receptor interaction. Ann N Y Acad Sci 2001;949:44-57.
8. Sieber PR. Treatment of bicalutamide-induced breast events. Expert Rev Anticancer Ther 2007;7:1773-9.
9. Klotz L. Maximal androgen blockade for advanced prostate cancer. Best Pract Res Clin Endocrinol Metab 2008;22:331-40.
10. Baek SH, Ohgi KA, Nelson CA, et al. Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. Proc Natl Acad Sci U S A 2006;103:3100-5.
11. Monge A, Jagla M, Lapouge G, et al. Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer. Cell Mol Life Sci 2006;63:487-97.
12. Yoshida T, Kinoshita H, Segawa T, et al. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res 2005;65:9611-6.
13. Berrevoets CA, Veldscholte J, Mulder E. Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors. J Steroid Biochem Mol Biol 1993;46:731-6.
14. Narayanan R, Adigun AA, Edwards DP, Weigel NL. Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. Mol Cell Biol 2005;25:264-77.
15. Narayanan R, Allen MR, Gaddy D, et al. Differential skeletal responses of hind limb unloaded rats on a vitamin D-deficient diet to 1,25-dihydroxyvitamin D3 and its analog, seocalcitol (EB1089). Bone 2004;35:134-43.
16. Marcelli M, Stenoien DL, Szafran AT, et al. Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J Cell Biochem 2006;98:770-88.
17. Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res 2002;62:3298-307.
18. Narayanan R, Edwards DP, Weigel NL. Human progesterone receptor displays cell cycle-dependent changes in transcriptional activity. Mol Cell Biol 2005;25:2885-98.
19. Matias PM, Donner P, Coelho R, et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 2000;275: 26164-71.
20. Hodgson MC, Astapova I, Hollenberg AN, Balk SP. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res 2007;67:8388-95.
21. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90.
22. Shi XB, Xue L, Zou JX, et al. Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells. Prostate 2008;68:1816-26.
23. Hara T, Miyazaki J, Araki H, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003;63:149-53.
24. Sack JS, Kish KF, Wang C, et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci U S A 2001;98:4904-9.
25. Bohl CE, Miller DD, Chen J, Bell CE, Dalton JT. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem 2005;280:37747-54.
26. Tuxhorn JA, McAlhany SJ, Yang F, Dang TD, Rowley DR. Inhibition of transforming growth factor-β activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 2002;62:6021-5.
27. Hershberger LG, Shipley EG, Meyer RK. Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method. Proc Soc Exp Biol Med 1953;83:175-80.
28. 2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther 2007;6:178-84.
29. Fan L, Yang X, Du J, et al. A novel role of p38 á MAPK in mitotic progression independent of its kinase activity. Cell Cycle 2005;4:1616-24.
30. Shiozaki K, Russell P. Cell-cycle control linked to extracellular environment by MAP kinase pathway in fission yeast. Nature 1995;378:739-43.
31. Bradham C, McClay DR. p38 MAPK in development and cancer. Cell Cycle 2006;5:824-8.
32. Gioeli D, Black BE, Gordon V, et al. Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol Endocrinol 2006;20:503-15.
33. Stenoien DL, Patel K, Mancini MG, et al. FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent. Nat Cell Biol 2001;3:15-23.
34. van Royen ME, Cunha SM, Brink MC, et al. Compartmentalization of androgen receptor protein-protein interactions in living cells. J Cell Biol 2007;177:63-72.
35. Farla P, Hersmus R, Trapman J, Houtsmuller AB. Antiandrogens prevent stable DNA-binding of the androgen receptor. J Cell Sci 2005; 118:4187-98.
36. Xiao YQ, Malcolm K, Worthen GS, et al. Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-â. J Biol Chem 2002;277: 14884-93.